PCRX Key Statistics, Chart & Performance
The current stock price of PCRX is 23.7 USD. In the past month the price increased by 10.85%. In the past year, price increased by 22.99%.
PCRX Latest News, Press Relases and Analysis
PCRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.11 | 1.00T | ||
| JNJ | JOHNSON & JOHNSON | 19.78 | 494.73B | ||
| MRK | MERCK & CO. INC. | 11.56 | 252.74B | ||
| PFE | PFIZER INC | 7.9 | 143.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.5 | 100.12B | ||
| ZTS | ZOETIS INC | 20.07 | 56.08B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.71 | 23.03B | ||
| VTRS | VIATRIS INC | 4.59 | 12.32B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.56 | 11.24B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.66 | 8.39B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.51B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.37B |
Related stock screener links
About PCRX
Company Profile
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Brisbane California, California and currently employs 790 full-time employees. The company went IPO on 2011-02-03. The firm has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The firm is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
Company Info
PACIRA BIOSCIENCES INC
2000 Sierra Point Parkway, Suite 900
Brisbane California CALIFORNIA 07054 US
CEO: David Stack
Employees: 789
Phone: 16502428052
PACIRA BIOSCIENCES INC / PCRX FAQ
What does PACIRA BIOSCIENCES INC do?
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Brisbane California, California and currently employs 790 full-time employees. The company went IPO on 2011-02-03. The firm has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The firm is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
What is the stock price of PACIRA BIOSCIENCES INC today?
The current stock price of PCRX is 23.7 USD. The price increased by 0.55% in the last trading session.
Does PACIRA BIOSCIENCES INC pay dividends?
PCRX does not pay a dividend.
How is the ChartMill rating for PACIRA BIOSCIENCES INC?
PCRX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What do analysts say about PACIRA BIOSCIENCES INC (PCRX) stock?
13 analysts have analysed PCRX and the average price target is 37.74 USD. This implies a price increase of 59.24% is expected in the next year compared to the current price of 23.7.
What is the Price/Earnings (PE) ratio of PACIRA BIOSCIENCES INC (PCRX)?
The PE ratio for PACIRA BIOSCIENCES INC (PCRX) is 7.98. This is based on the reported non-GAAP earnings per share of 2.97 and the current share price of 23.7 USD.
What is the market capitalization of PCRX stock?
PACIRA BIOSCIENCES INC (PCRX) has a market capitalization of 1.02B USD. This makes PCRX a Small Cap stock.
PCRX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to PCRX. When comparing the yearly performance of all stocks, PCRX turns out to be only a medium performer in the overall market: it outperformed 67.71% of all stocks.
PCRX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to PCRX. While PCRX has a great profitability rating, there are some minor concerns on its financial health.
PCRX Financial Highlights
Over the last trailing twelve months PCRX reported a non-GAAP Earnings per Share(EPS) of 2.97. The EPS decreased by -6.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.99% | ||
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| Debt/Equity | 0.52 |
PCRX Forecast & Estimates
13 analysts have analysed PCRX and the average price target is 37.74 USD. This implies a price increase of 59.24% is expected in the next year compared to the current price of 23.7.
For the next year, analysts expect an EPS growth of -8.75% and a revenue growth 5.37% for PCRX